Adverse events related to AFM13 and combination treatment, respectively
| . | AFM13 . | AFM13 + pembrolizumab . | ||
|---|---|---|---|---|
| . | All grades, ≥10% (n = 30), n (%) . | ≥Grade 3 (n = 30), n (%) . | All grades, ≥10%, n (%) . | ≥Grade 3 (n = 30), n (%) . |
| Any AE | 29 (97) | 7 (23) | 22 (73) | 2 (7) |
| IRR | 27 (90) | 4 (13) | 8 (27) | 1 (3) |
| Rash | 9 (30) | — | 6 (20) | — |
| Nausea | 7 (23) | 1 (3) | 7 (23) | 1 (3) |
| Pyrexia | 7 (23) | — | 4 (13) | — |
| Fatigue | 5 (17) | — | 5 (17) | — |
| Diarrhea | 6 (20) | — | 5 (17) | — |
| Headache | 5 (17) | — | 3 (10) | — |
| Elevated ALT | 4 (13) | — | 3 (10) | — |
| Elevated AST | 4 (13) | 1 (3) | 2 (7) | — |
| Neutropenia | 2 (7) | 1 (3) | 2 (7) | — |
| Gastritis | 1 (3) | 1 (3) | 1 (3) | 1 (3) |
| Vomiting | 2 (7) | 1 (3) | 1 (3) | 1 (3) |
| Hypotension | 1 (3) | 1 (3) | — | — |
| Thrombocytopenia | 2 (7) | — | 2 (7) | — |
| URTI | 2 (7) | — | 2 (7) | — |
| . | AFM13 . | AFM13 + pembrolizumab . | ||
|---|---|---|---|---|
| . | All grades, ≥10% (n = 30), n (%) . | ≥Grade 3 (n = 30), n (%) . | All grades, ≥10%, n (%) . | ≥Grade 3 (n = 30), n (%) . |
| Any AE | 29 (97) | 7 (23) | 22 (73) | 2 (7) |
| IRR | 27 (90) | 4 (13) | 8 (27) | 1 (3) |
| Rash | 9 (30) | — | 6 (20) | — |
| Nausea | 7 (23) | 1 (3) | 7 (23) | 1 (3) |
| Pyrexia | 7 (23) | — | 4 (13) | — |
| Fatigue | 5 (17) | — | 5 (17) | — |
| Diarrhea | 6 (20) | — | 5 (17) | — |
| Headache | 5 (17) | — | 3 (10) | — |
| Elevated ALT | 4 (13) | — | 3 (10) | — |
| Elevated AST | 4 (13) | 1 (3) | 2 (7) | — |
| Neutropenia | 2 (7) | 1 (3) | 2 (7) | — |
| Gastritis | 1 (3) | 1 (3) | 1 (3) | 1 (3) |
| Vomiting | 2 (7) | 1 (3) | 1 (3) | 1 (3) |
| Hypotension | 1 (3) | 1 (3) | — | — |
| Thrombocytopenia | 2 (7) | — | 2 (7) | — |
| URTI | 2 (7) | — | 2 (7) | — |
URTI, upper respiratory tract infection.